Broken String Biosciences

Broken String Biosciences is a Cambridge, UK-based biotechnology company powering the future of gene editing development through its INDUCE-seq platform. Founded in 2020 at the Wellcome Genome Campus, the company provides the BreakMap platform for genome-wide on- and off-target DNA break analysis, enabling cell and gene therapy developers to generate high-quality safety data earlier and faster. INDUCE-seq supports the full development arc from discovery screening through IND-enabling studies, working across diverse cell types and nuclease systems with a single standardized workflow. In 2026, the company filed an FDA Master File for INDUCE-seq as regulatory expectations for genome-wide off-target analysis intensify, and has expanded commercially into Southeast Asia.